Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
32
FOLD Quote, Financials, Valuation and Earnings
Last price:
$6.15
Seasonality move
:
20.05%
Day range:
$6.09 - $6.23
52-week range:
$5.81 - $12.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.45x
P/B ratio:
9.77x
Volume:
4.8M
Avg. volume:
5.2M
1-year change:
-40.96%
Market cap:
$1.9B
Revenue:
$528.3M
EPS (TTM):
-$0.09
Analysts' Opinion
-
Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.82, Amicus Therapeutics has an estimated upside of 157.63% from its current price of $6.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $6.14.
Fair Value
-
According to the consensus of 11 analysts, Amicus Therapeutics has 157.63% upside to fair value with a price target of $15.82 per share.
FOLD vs. S&P 500
-
Over the past 5 trading days, Amicus Therapeutics has overperformed the S&P 500 by 0.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amicus Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amicus Therapeutics has grown year-over-year revenues for 31 quarters straight. In the most recent quarter Amicus Therapeutics reported revenues of $125.2M.
Earnings Growth
-
Amicus Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Amicus Therapeutics reported earnings per share of -$0.07.
Enterprise value:
2B
EV / Invested capital:
3.48x
Price / LTM sales:
3.45x
EV / EBIT:
44.73x
EV / Revenue:
3.74x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1,262.95x
Price / Operating cash flow:
1,166.81x
Enterprise value / EBITDA:
37.87x
Gross Profit (TTM):
$492.1M
Return On Assets:
-3.83%
Net Income Margin (TTM):
-5.41%
Return On Equity:
-17.7%
Return On Invested Capital:
-5.29%
Operating Margin:
-6.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $336.8M | $423.5M | $543.1M | $110.4M | $125.2M | |
| Gross Profit | $298.8M | $379.5M | $492.1M | $96.8M | $113.6M | |
| Operating Income | -$171.9M | -$57.8M | $47.8M | -$21.7M | -$8M | |
| EBITDA | -$167.8M | -$81M | $53.6M | -$29M | -$4.8M | |
| Diluted EPS | -$0.70 | -$0.49 | -$0.09 | -$0.16 | -$0.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $502.9M | $518.9M | $399.7M | $431.2M | $510.8M | |
| Total Assets | $810M | $826.9M | $700.5M | $721.8M | $789.8M | |
| Current Liabilities | $99.7M | $129.7M | $138.4M | $142.1M | $152.9M | |
| Total Liabilities | $559.1M | $588.3M | $597.9M | $591.1M | $596.3M | |
| Total Equity | $250.9M | $238.6M | $102.6M | $130.7M | $193.6M | |
| Total Debt | $389.8M | $390M | $392.7M | $388.4M | $390.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$126.3M | -$80.7M | $3.6M | -$29.7M | $7.8M | |
| Cash From Investing | $70.4M | $69.3M | -$41M | $7.5M | -$32.9M | |
| Cash From Financing | -$7.1M | $56.2M | $6.7M | -$13.3M | -$11.7M | |
| Free Cash Flow | -$131.2M | -$88M | $1.6M | -$31.5M | $7.5M | |
FOLD
Sector
Market Cap
$1.9B
$34.2M
Price % of 52-Week High
48.54%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-0.67%
-0.6%
1-Year Price Total Return
-40.96%
-35.99%
Beta (5-Year)
0.538
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.12
200-day SMA
Sell
Level
$9.25
Bollinger Bands (100)
Sell
Level
6.51 - 9.35
Chaikin Money Flow
Buy
Level
40M
20-day SMA
Sell
Level
$6.18
Relative Strength Index (RSI14)
Sell
Level
44.75
ADX Line
Sell
Level
22.6
Williams %R
Neutral
Level
-50
50-day SMA
Sell
Level
$6.61
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
434.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.722)
Sell
CA Score
(Annual)
Level (-1.3347)
Buy
Beneish M-Score
(Annual)
Level (-2.4418)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.7794)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Stock Forecast FAQ
In the current month, FOLD has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The FOLD average analyst price target in the past 3 months is $15.82.
-
Where Will Amicus Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amicus Therapeutics share price will rise to $15.82 per share over the next 12 months.
-
What Do Analysts Say About Amicus Therapeutics?
Analysts are divided on their view about Amicus Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amicus Therapeutics is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Amicus Therapeutics's Price Target?
The price target for Amicus Therapeutics over the next 1-year time period is forecast to be $15.82 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is FOLD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amicus Therapeutics is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FOLD?
You can purchase shares of Amicus Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amicus Therapeutics shares.
-
What Is The Amicus Therapeutics Share Price Today?
Amicus Therapeutics was last trading at $6.15 per share. This represents the most recent stock quote for Amicus Therapeutics. Yesterday, Amicus Therapeutics closed at $6.14 per share.
-
How To Buy Amicus Therapeutics Stock Online?
In order to purchase Amicus Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 29.48% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 20.55% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 17.78% over the past day.
